CD19 and B-cell non-Hodgkin lymphoma: We detected high peak proportions of CD19-modified T cells in the 26 patients with B-ALL who exhibited therapeutic responses (median: 132,469.2 copies/μg genomic DNA; range: 613.7–2,135,476 copies/μg genomic DNA) and in the 7 patients with B-cell lymphoma who exhibited a therapeutic response (median: 13,719.36 copies/μg genomic DNA; range: 188.53–52,275.96 copies/μg genomic DNA).